Seer Files Patent Infringement Lawsuit Against Nanomics

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 6 days ago

0mins

SEER-1.74%

Should l Buy SEER?

Source: seekingalpha

Patent Infringement Lawsuit: Seer (SEER) announced on Wednesday that it has filed a patent infringement lawsuit against Nanomics Biotechnology, alleging infringement of five U.S. patents related to nanoparticle protein enrichment technology, demonstrating Seer's commitment to protecting its intellectual property.
Collaboration Involvement: Brigham and Women’s Hospital has joined the lawsuit, indicating the complexity and significance of the case, which could have a substantial impact on Seer's market position regarding its Proteograph product suite.
Seeking Damages: Seer is pursuing monetary damages and injunctive relief in the lawsuit, reflecting its strong opposition to Nanomics' alleged infringement through its Proteonano kits and workstations, which may affect Nanomics' business operations.
Commitment to Technology Protection: CEO Omid Farokhzad stated that the company would aggressively defend its proteomics technology portfolio, highlighting Seer's emphasis on its technology and determination in future market competition.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy SEER?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on SEER

About SEER

Seer, Inc. is a life sciences company. It is developing products that open a new gateway to the proteome. Its Proteograph product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform proteomic analysis at scale in a matter of hours. The Proteograph has detected over 36,000 proteins across multiple species, and its performance and capabilities have been demonstrated in over 33 peer-reviewed publications, preprints and reviews. The Proteograph Product Suite is detector-agnostic and is adaptable to other protein detection instruments. The MS component of the Proteograph workflow is either provided by the researcher’s laboratory, can be outsourced to a third-party provider, or be run through the Seer Technology Access Center (STAC), which is its in-house service program. It has launched Proteograph XT, which enhances the sample throughput of the Proteograph Product Suite and MS instrument.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Seer Acquisition Offer Raised to $2.40 per Share

5 days agoseekingalpha

Acquisition Proposal Increase: Investors Bradley Radoff and Michael Torok have raised their acquisition offer for Seer to $2.40 per share in cash, plus a contingent value right tied to future asset sales, indicating recognition of the company's value.
Significant Premium: This proposal represents a 42% premium over Seer's unaffected share price from April 10, reflecting investor confidence in the company's potential value and possibly prompting management to reconsider its strategic direction.
Investor Ownership Stake: The investor group currently owns about 7.8% of Seer and has criticized the company's poor operating performance, urging the board to take this proposal seriously, highlighting shareholder concerns regarding corporate governance.
Disappointing Earnings Outlook: Seer's Q1 2026 earnings report revealed a GAAP EPS of -$0.30 and revenue of $2.8 million, both missing market expectations, which further exacerbates investor concerns about the company's future growth prospects.

Seer, Inc. Q1 2026 Earnings Call Insights

6 days agoseekingalpha

Weak Revenue Performance: Seer reported total revenue of $2.8 million for Q1 2026, a 33% decline from $4.2 million in Q1 2025, reflecting ongoing depressed academic funding and increased competitive pressures that pose significant market challenges.
Strategic Adjustments: The company appointed a new Chief Commercial Officer to drive sales momentum and filed a patent infringement lawsuit against Nanomix Biotechnology, demonstrating Seer's commitment to protecting its intellectual property and enhancing its competitive position in the market.
Severe Financial Condition: The net loss for Q1 was $16.8 million with operating expenses reaching $18.2 million; despite repurchasing shares worth $24.5 million, the free cash flow remained negative at $15.7 million, indicating tight liquidity.
Outlook Reaffirmation: Despite a weak start, Seer reaffirmed its full-year revenue guidance of $16 million to $18 million for 2026, with management expressing optimism about a rebound in the second half of the year as customer reorder dynamics are expected to improve.